Thiosemicarbazones: the new wave in cancer treatment

The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase II  in Breast Cancer Cells

(2009) V. A. Rao et al.   CANCER RESEARCH

2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity

(2009) Des R. Richardson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells

(2008) Egarit Noulsri et al.   AMERICAN JOURNAL OF HEMATOLOGY

p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation-Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia

(2008) P. A. Link et al.   CANCER RESEARCH

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia

(2008) Olatoyosi M. Odenike et al.   INVESTIGATIONAL NEW DRUGS

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

(2008) Steven Attia et al.   INVESTIGATIONAL NEW DRUGS

Iron Chelators of the Dipyridylketone Thiosemicarbazone Class: Precomplexation and Transmetalation Effects on Anticancer Activity

(2008) Paul V. Bernhardt et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

(2007) Judith E. Karp et al.   LEUKEMIA RESEARCH